{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-001933","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2024-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.338213+00:00","generated_at":"2026-06-07T04:18:34.123191+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NewAmsterdam Pharma announces 2024 strategic priorities; Phase 3 readouts in 3Q/4Q 2024","bullets":["Expects topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024.","Expects topline data from Phase 3 BROADWAY trial in ASCVD in 4Q 2024.","Plans to initiate TANDEM Phase 3 FDC trial in 1Q 2024; topline data in 1Q 2025.","Completes enrollment in PREVAIL CVOT in 1Q 2024; topline data in 2026.","Cash sufficient to fund operations through 2026, beyond three Phase 3 readouts."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-001933","json":"https://secwatch.observer/filing/0001193125-24-001933.json","markdown":"https://secwatch.observer/filing/0001193125-24-001933.md","text":"https://secwatch.observer/filing/0001193125-24-001933.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524001933/0001193125-24-001933-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524001933/d822244d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:18:34.123191+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}